ABCG2 downregulation in glioma stem cells enhances the therapeutic efficacy of demethoxycurcumin

Oncotarget

Volumn 8, Issue 26, 2017, Pages 43237-43247

  Chen, Long ^a,b   Shi, Lei ^c   Wang, Wenhua ^b   Zhou, Youxin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^c KUNSHAN FIRST PEOPLE S HOSPITAL AFFILIATED TO JIANGSU UNIVERSITY   (China)

Author keywords

ABCG2; Caspase 3; Demethoxycurcumin; Glioma stem cells; Reactive oxygen species

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CASPASE 3; CYTOCHROME C; DEMETHOXYCURCUMIN; REACTIVE OXYGEN METABOLITE; TEMOZOLOMIDE; ABCG2 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; CURCUMIN; HEPTANE DERIVATIVE; TUMOR PROTEIN;

ABCG2 GENE; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; ASTROCYTE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GLIOMA; GLIOMA STEM CELL; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; CANCER STEM CELL; CELL PROLIFERATION; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; GENETIC TRANSFECTION; GLIOBLASTOMA; METABOLISM; NUDE MOUSE; PATHOLOGY; RANDOMIZATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY G, MEMBER 2; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; DIARYLHEPTANOIDS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GLIOBLASTOMA; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; RANDOM ALLOCATION; REACTIVE OXYGEN SPECIES; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85021269214     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.18018     Document Type: Article

References (30)

1. Stupp R, Tonn JC, Brada M, Pentheroudakis G; ESMO Guidelines Working Group. High-grade malignant glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21:v190-3
2. Athanassiou H, Synodinou M, Maragoudakis E, Paraskevaidis M, Verigos C, Misailidou D, Antonadou D, Saris G, Beroukas K, Karageorgis P. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol. 2005; 23:2372-7
3. Vescovi AL, Galli R, Reynolds BA. Brain tumour stem cells. Nat Rev Cancer. 2006; 6:425-36
4. Gong X, Schwartz PH, Linskey ME, Bota DA. Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy. Neurology. 2011; 76:1126-34
5. Robey RW, Steadman K, Polgar O, Bates SE. ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy. Cancer Biol Ther. 2005; 4:184-7
6. Bebes A, Nagy T, Bata-Csörgo Z, Kemény L, Dobozy A, Széll M. Specific inhibition of the ABCG2 transporter could improve the efficacy of photodynamic therapy. J Photochem Photobiol B. 2011; 105:162-6
7. Jia Q, Zhang X, Deng T, Gao J. Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+) CD133(+) liver cancer stem cells. Cell Reprogram. 2013; 15:143-50
8. Phan NL, Trinh NV, Pham PV. Low concentrations of 5-aza-2'-deoxycytidine induce breast cancer stem cell differentiation by triggering tumor suppressor gene expression. Onco Targets Ther. 2015; 9:49-59
9. Jia Y, Chen J, Zhu H, Jia ZH, Cui MH. Aberrantly elevated redox sensing factor Nrf2 promotes cancer stem cell survival via enhanced transcriptional regulation of ABCG2 and Bcl-2/Bmi-1 genes. Oncol Rep. 2015; 34:2296-304
10. Shi L, Wang Z, Sun G, Wan Y, Guo J, Fu X. miR-145 inhibits migration and invasion of glioma stem cells by targeting ABCG2. Neuromolecular Med. 2014; 16:517-28
11. Xu ZY, Wang K, Li XQ, Chen S, Deng JM, Cheng Y, Wang ZG. The ABCG2 transporter is a key molecular determinant of the efficacy of sonodynamic therapy with Photofrin in glioma stem-like cells. Ultrasonics. 2013; 53:232-8
12. Jin Y, Bin ZQ, Qiang H, Liang C, Hua C, Jun D, Dong WA, Qing L. ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma. J Cancer Res Clin Oncol. 2009; 135:1369-76
13. Shi L, Fei X, Wang Z. Demethoxycurcumin was prior to temozolomide on inhibiting proliferation and induced apoptosis of glioblastoma stem cells. Tumour Biol. 2015; 36:7107-19
14. Shen S, Callaghan D, Juzwik C, Xiong H, Huang P, Zhang W. ABCG2 reduces ROS-mediated toxicity and inflammation: a potential role in Alzheimer's disease. J Neurochem. 2010; 114:1590-604
15. Oliva CR, Moellering DR, Gillespie GY, Griguer CE. Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production. PLoS One. 2011; 6:e24665
16. Ravindran J, Prasad S, Aggarwal BB. Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J. 2009; 11:495-510
17. Wang W, Zhang L, Wang Z, Yang F, Wang H, Liang T, Wu F, Lan Q, Wang J, Zhao J. A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma. Oncotarget. 2016; 7:69991-9. doi: 10.18632/oncotarget.11726
18. Bleau AM, Huse JT, Holland EC. The ABCG2 resistance network of glioblastoma. Cell Cycle. 2009; 8:2936-44
19. Yodkeeree S, Chaiwangyen W, Garbisa S, Limtrakul P. Curcumin, demethoxycurcumin and bisdemethoxycurcumin differentially inhibit cancer cell invasion through the downregulation of MMPs and uPA. J Nutr Biochem. 2009; 20:87-95
20. Luthra PM, Kumar R, Prakash A. Demethoxycurcumin induces Bcl-2 mediated G2/M arrest and apoptosis in human glioma U87 cells. Biochem Biophys Res Commun. 2009; 384:420-5
21. Limtrakul P, Chearwae W, Shukla S, Phisalphong C, Ambudkar SV. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol Cell Biochem. 2007; 296:85-95
22. Zhang X, Chen Q, Wang Y, Peng W, Cai H. Effects of curcumin on ion channels and transporters. Front Physiol. 2014; 5:94
23. Shi L, Fei X, Wang Z. Demethoxycurcumin was prior to temozolomide on inhibiting proliferation and induced apoptosis of glioblastoma stem cells. Tumour Biol. 2015; 36:7107-19
24. Lapidus RG, Carter-Cooper BA, Sadowska M, Choi EY, Wonodi O, Muvarak N, Natarajan K, Pidugu LS, Jaiswal A, Toth EA, Rassool FV, Etemadi A, Sausville EA, et al. Hydroxylated dimeric naphthoquinones increase the generation of reactive oxygen species, induce apoptosis of acute myeloid leukemia cells and are not substrates of the multidrug resistance proteins ABCB1 and ABCG2. Pharmaceuticals (Basel). 2016; 9:E4. doi: 10.3390/ph9010004
25. Buranrat B, Senggunprai L, Prawan A, Kukongviriyapan V. Simvastatin and atorvastatin as inhibitors of proliferation and inducers of apoptosis in human cholangiocarcinoma cells. Life Sci. 2016; 153:41-9
26. Zhelev Z, Ivanova D, Lazarova D, Aoki I, Bakalova R, Saga T. Docosahexaenoic acid sensitizes leukemia lymphocytes to barasertib and everolimus by ROS-dependent mechanism without affecting the level of ROS and viability of normal lymphocytes. Anticancer Res. 2016; 36:1673-82
27. Li QC, Liang Y, Tian Y, Hu GR. Arctigenin induces apoptosis in colon cancer cells through ROS/p38MAPK pathway. J BUON. 2016; 21:87-94
28. Shen S, Callaghan D, Juzwik C, Xiong H, Huang P, Zhang W. ABCG2 reduces ROS-mediated toxicity and inflammation: a potential role in Alzheimer's disease. J Neurochem. 2010; 114:1590-604
29. Ding Y, Wang H, Niu J, Luo M, Gou Y, Miao L, Zou Z, Cheng Y. Induction of ROS overload by alantolactone prompts oxidative DNA damage and apoptosis in colorectal cancer cells. Int J Mol Sci. 2016; 17:558
30. Darling JL. The in vitro biology of human brain tumors. In: Thomas DG, editor. Neuro-oncology: primary malignant brain tumors. Baltimore: Johns Hopkins University Press; 1990 p. 1-25